We demonstrate the utility of the dataset in identifying clinically-actionable targets by focusing on galectin-1, a β-galactoside binding protein that has been previously implicated in cancer, tissue fibrosis and immunoregulation (56, 57) although its role in myeloid malignancies has not been fully investigated. The gene discussed is LGALS1; the disease is cancer.